Article | August 19, 2021

Looking Ahead: The Future Of Cell Therapy In Oncology

iStock-1278412677-oncology-cancer-patient

For the field of cell therapy, the future is promising. With chimeric antigen receptor T-cell (CAR-T) therapies steadily advancing, there are now numerous FDA approved therapies for patients with blood-borne cancers, including B-cell non-Hodgkin’s lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). In fact, the FDA recently approved Abecma (idecabtagene vicleucel), the first cell therapy approved by the FDA for heavily pre-treated adult patients with multiple myeloma.

However, in the face of these advancements, there are still challenges to overcome, including the length of time required to manufacture cell therapies, high costs, and logistical challenges.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader